Assignee
AUTOLUS LTD
GB·53 granted patents·75 pending applications·87 citations·filing 2015–2025
Top patents by PatentIndex Score
128 records- 0196US11034750B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2018·Granted Jun 15, 2021·8 cites·7 claims
- 0295US12187769B2CellAUTOLUS LTD·Filed 2023·Granted Jan 7, 2025·2 cites·5 claims
- 0395US11091532B2T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptorAUTOLUS LTD·Filed 2015·Granted Aug 17, 2021·8 cites·16 claims
- 0494US11590170B2Chimeric antigen receptorAUTOLUS LTD·Filed 2022·Granted Feb 28, 2023·3 cites·6 claims
- 0594US11434293B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2021·Granted Sep 6, 2022·7 cites·10 claims
- 0693US10981970B2Chimeric antigen receptor (CAR) comprising a CD22-binding domainAUTOLUS LTD·Filed 2018·Granted Apr 20, 2021·4 cites·8 claims
- 0793US10800854B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2016·Granted Oct 13, 2020·6 cites·22 claims
- 0892US11440961B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2018·Granted Sep 13, 2022·7 cites·11 claims
- 0992US10800855B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2018·Granted Oct 13, 2020·4 cites·15 claims
- 1090US11058722B2Chimeric antigen receptor comprising a cartilage-oligomeric matrix protein (comp) coiled-coil spacer domainAUTOLUS LTD·Filed 2016·Granted Jul 13, 2021·4 cites·13 claims
- 1190US10954530B2Retroviral and lentiviral vectorsAUTOLUS LTD·Filed 2016·Granted Mar 23, 2021·5 cites·12 claims
- 1289US11851672B2CAR T-cells comprising transcriptional circuitsAUTOLUS LTD·Filed 2018·Granted Dec 26, 2023·3 cites·2 claims
- 1389US11365262B2CellAUTOLUS LTD·Filed 2016·Granted Jun 21, 2022·4 cites·19 claims
- 1489US2025353893A1CellAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 1587US12049510B2Chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Jul 30, 2024·2 cites·14 claims
- 1687US11180553B2Chimeric antigen receptorAUTOLUS LTD·Filed 2017·Granted Nov 23, 2021·4 cites·12 claims
- 1786US12398194B2Cell lexpressing two chimeric antigen receptors (CARs) at the cell surfaceAUTOLUS LTD·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 1886US11479613B2Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteinsAUTOLUS LTD·Filed 2020·Granted Oct 25, 2022·1 cites·11 claims
- 1986US2024033292A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2085US11103532B2Chimeric proteinAUTOLUS LTD·Filed 2019·Granted Aug 31, 2021·2 cites·21 claims
- 2184US2024033289A1CellAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 2283US12234295B2Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereofAUTOLUS LTD·Filed 2022·Granted Feb 25, 2025·0 cites·22 claims
- 2383US11701386B2CellAUTOLUS LTD·Filed 2018·Granted Jul 18, 2023·1 cites·7 claims
- 2482US11959084B2Nucleic acid constructAUTOLUS LTD·Filed 2019·Granted Apr 16, 2024·1 cites·21 claims
- 2582US2025368715A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 2681US11982673B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·10 claims
- 2781US11982672B2MethodsAUTOLUS LTD·Filed 2022·Granted May 14, 2024·0 cites·8 claims
- 2881US11885806B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·10 claims
- 2981US11885807B2Method for depleting malignant T-cellsAUTOLUS LTD·Filed 2022·Granted Jan 30, 2024·0 cites·8 claims
- 3081US2025388929A1Retroviral and Lentiviral VectorsAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3181US2023194535A1MethodsAUTOLUS LTD·Filed 2022·Application pending·0 cites
- 3281US2025197464A1CellAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3380US11578126B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2019·Granted Feb 14, 2023·1 cites·21 claims
- 3480US10919951B2Chimeric antigen receptorAUTOLUS LTD·Filed 2018·Granted Feb 16, 2021·2 cites·7 claims
- 3580US2025277047A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 3679US11466070B2Signalling systemAUTOLUS LTD·Filed 2017·Granted Oct 11, 2022·2 cites·12 claims
- 3779US2024301088A1Chimeric antigen receptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 3878US12454578B2Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptorsAUTOLUS LTD·Filed 2022·Granted Oct 28, 2025·0 cites·4 claims
- 3978US11385233B2Methods of depleting malignant T-cellsAUTOLUS LTD·Filed 2018·Granted Jul 12, 2022·1 cites·9 claims
- 4078US11345734B2Chimeric T cellAUTOLUS LTD·Filed 2016·Granted May 31, 2022·1 cites·5 claims
- 4178US11242377B2Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomainsAUTOLUS LTD·Filed 2016·Granted Feb 8, 2022·1 cites·35 claims
- 4278US2024076352A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 4378US2025314655A1MethodsAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 4478US2025019434A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4578US2023346838A1Chimeric Antigen ReceptorAUTOLUS LTD·Filed 2023·Application pending·0 cites
- 4678US2024384278A1Nucleic acid constructAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4777US2025333505A1T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibodyAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 4877US2025333538A1Chimeric cytokine receptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 4977US2026062458A1Chimeric antigen receptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 5076US12516119B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2022·Granted Jan 6, 2026·0 cites·6 claims
Showing the top 50 of 128 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when AUTOLUS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →